Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2022, with a specific reporting date of January 11, 2022. The document serves as a transaction notification regarding insider trading activities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $43.8500 per ADS.
- Total Volume: 1,223.605 ADSs (comprising 1,037.605 ADSs in one transaction and 186 ADSs in another).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely discloses the acquisition of company stock by an executive.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of a specific transaction executed on January 7, 2022, on the New York Stock Exchange (XNYS).
Key Facts for Investor Verification
- Executive Involved: Dr. H. Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: Acquisitions of ADSs within two separate accounts: the GSK Executive Supplemental Savings Plan and the GSK 401(k) Plan.
- Transaction Date: January 7, 2022.
- Market Context: Transactions occurred at a price of $43.85, reflecting the market value on the date of execution.